Can I Take Caffeine with MK-677 (Ibutamoren)?

What Kind of Interaction Exists Between Caffeine and MK-677?

The interaction is primarily pharmacodynamic, meaning the two compounds affect overlapping physiological systems rather than blocking each other's metabolism in a simple way. MK-677 is a selective, orally active ghrelin receptor agonist that drives pulsatile growth hormone (GH) release and raises IGF-1 concentrations. Caffeine is a non-selective adenosine receptor antagonist with well-documented effects on the sympathetic nervous system, heart rate, and vascular tone.

There is also a secondary pharmacokinetic dimension worth understanding. Caffeine is metabolized almost entirely by CYP1A2 in the liver. MK-677's metabolic pathway has not been characterized in publicly available Phase I pharmacokinetic data to the same depth, but ghrelin receptor agonists as a class can influence insulin and GH axes that indirectly modulate hepatic enzyme activity. Until formal drug-interaction studies are published, treating the CYP1A2 question as unresolved is the most defensible clinical position.

Pharmacodynamic Overlap: The Blood Pressure Problem

Caffeine raises systolic blood pressure by 3 to 15 mmHg acutely through adenosine blockade and catecholamine release, an effect documented across more than a dozen controlled studies and summarized in a 2012 meta-analysis of 34 trials published in the Journal of Hypertension [1]. The pressor effect is most pronounced in caffeine-naive individuals and people with underlying hypertension.

MK-677, in turn, caused fluid retention and mild increases in blood pressure in the MK-677-in-elderly trial (N=65) published in the Annals of Internal Medicine in 1998 [2]. Two participants in that trial required dose reduction due to edema and worsening hypertension. Taking both compounds simultaneously stacks two separate pressor mechanisms, which is clinically relevant for anyone whose resting blood pressure is already 130/85 mmHg or higher.

Pharmacodynamic Overlap: Glucose and Insulin Sensitivity

This is the more consequential shared risk. MK-677 consistently raises fasting glucose in clinical trials. In the 2-year elderly hip-fracture trial by Adunsky et al. (N=123), fasting glucose rose by approximately 0.3 to 0.5 mmol/L in the MK-677 arm compared to placebo [3]. The mechanism is GH-mediated: supraphysiologic GH pulses promote hepatic glucose output and reduce peripheral insulin sensitivity.

Caffeine compounds this. A crossover study published in Diabetes Care (N=14) found that 5 mg/kg caffeine reduced whole-body insulin sensitivity by roughly 15% in the 3 hours post-ingestion [4]. That acute insulin-desensitizing effect adds directly onto MK-677's chronic background effect on glucose regulation.

People with prediabetes, insulin resistance, or metabolic syndrome face the highest risk from this combination.

Does Caffeine Affect CYP1A2 and MK-677 Metabolism?

This question is harder to answer definitively because MK-677's full cytochrome P450 interaction profile has not been published in peer-reviewed literature. What is known comes from indirect evidence.

CYP1A2 and Caffeine's Own Metabolism

Caffeine is one of the most well-studied CYP1A2 substrates in clinical pharmacology. Drugs or compounds that inhibit CYP1A2 (fluvoxamine, ciprofloxacin, some polyphenols) can raise caffeine plasma concentrations significantly, extending its half-life from a typical 3 to 5 hours up to 10 hours in heavy inhibition scenarios [5].

Where MK-677 Fits

MK-677 does not appear on standard CYP1A2 inhibitor or inducer lists in the FDA drug interaction database or in Natural Medicines Comprehensive Database entries reviewed as of early 2025. This absence reflects a lack of formal study rather than confirmed safety. Because MK-677 is sold exclusively as a research chemical without FDA oversight of its manufacturing, lot-to-lot purity varies substantially, and contaminants in some products could theoretically carry enzyme-inhibiting activity.

The practical takeaway: there is no strong published evidence that MK-677 alters caffeine metabolism, but the data gap is real. Unusual caffeine sensitivity, prolonged jitteriness, or insomnia while using MK-677 could indicate altered caffeine clearance worth investigating with a clinician.

Blood Pressure: How Much Additional Risk Does the Combination Add?

Combining two compounds that each raise blood pressure is additive at minimum, possibly supra-additive in individuals with sympathetic nervous system hyperreactivity.

Caffeine's Acute Pressor Effect

In caffeine-naive adults, a single 250 mg dose of caffeine raises systolic BP by an average of 8 to 10 mmHg within 30 to 60 minutes, based on the 2012 meta-analysis cited above [1]. In habitual coffee drinkers, the acute effect is blunted due to adenosine receptor upregulation, but the chronic hypertensive burden remains debated.

MK-677's Fluid-Retention Mechanism

MK-677 increases circulating IGF-1, which promotes renal sodium retention via IGF-1 receptors in the proximal tubule. This volume-expansion mechanism is distinct from caffeine's sympathetic pathway. The 1998 Annals of Internal Medicine trial in older adults found that 25 mg/day MK-677 for 12 months increased body water and raised systolic BP modestly but significantly in a subset of participants [2].

Who Should Be Most Concerned

Anyone with baseline systolic BP above 130 mmHg, stage 1 or stage 2 hypertension, or a history of cardiovascular disease should discuss this combination with a physician before proceeding. The American Heart Association's 2023 hypertension guidelines recommend keeping stimulant use minimal in this population [6].

Glucose and Insulin: A Closer Look at the Combined Effect

Both compounds degrade glucose control through different entry points, and the effects overlap in real time during morning use.

MK-677's Mechanism on Glucose

GH secretagogues produce supra-normal GH pulses. GH directly antagonizes insulin signaling at the post-receptor level via STAT5b-mediated upregulation of p85 alpha (a regulatory subunit of PI3K), reducing glucose uptake in skeletal muscle. In the Adunsky 2-year trial, HbA1c drifted upward by about 0.2 to 0.3% in the MK-677 arm, a change small enough to be statistically marginal but clinically meaningful in people near the prediabetes threshold of 5.7% [3].

Caffeine's Mechanism on Glucose

Caffeine raises plasma epinephrine, which suppresses insulin secretion from pancreatic beta cells and raises hepatic glucose output through glycogenolysis. The Diabetes Care crossover study showed that 5 mg/kg caffeine reduced insulin-stimulated glucose disposal by approximately 15% during a euglycemic-hyperinsulinemic clamp [4]. At a body weight of 80 kg, 5 mg/kg equals 400 mg, which is the upper end of a typical pre-workout or two large coffees.

Practical Monitoring Targets

Fasting glucose testing once monthly is a reasonable baseline for anyone using MK-677. Adding daily caffeine intake above 200 mg raises the case for more frequent checks, particularly if fasting glucose trends toward 100 mg/dL or higher.

Is There a Safe Dose Separation Strategy?

No randomized trial has tested dose-separation windows specifically for this combination. The guidance here is based on pharmacokinetic reasoning rather than direct evidence.

MK-677's Timing

MK-677 is typically taken at bedtime because GH secretion peaks nocturnally and ibutamoren's ghrelin agonism aligns best with that rhythm. Its half-life in published pharmacokinetic data is approximately 6 hours, but its biological effect on IGF-1 lasts 24 hours from a single dose, meaning time-of-day separation does not meaningfully reduce the interaction risk [7].

Caffeine's Timing

Caffeine's half-life averages 3 to 5 hours in healthy adults [5]. Morning caffeine intake is largely cleared by mid-afternoon in most people. Avoiding caffeine within 6 hours of bedtime is standard sleep-hygiene advice and aligns with taking MK-677 at night.

The functional recommendation: take MK-677 at bedtime, confine caffeine to the morning and early afternoon, and keep daily caffeine at or below 200 mg if blood pressure or glucose is already borderline.

The HealthRX clinical team uses the following decision framework for patients asking about MK-677 and caffeine simultaneously:

Step 1. Establish baseline blood pressure (3 readings on separate days), fasting glucose, and HbA1c before starting either compound.

Step 2. If baseline systolic BP is 130 mmHg or higher, or fasting glucose is 100 mg/dL or higher, discuss with a physician before adding MK-677.

Step 3. If proceeding, limit caffeine to 200 mg/day or less during the first 4 weeks and recheck blood pressure and fasting glucose at week 4.

Step 4. If week-4 fasting glucose has risen more than 10 mg/dL from baseline or systolic BP has risen more than 8 mmHg from baseline, reduce or eliminate caffeine intake and reassess MK-677 dose.

Step 5. After 12 weeks, obtain fasting glucose, HbA1c, and a full metabolic panel as a stable-state check.

What Do Clinical Trials Tell Us About MK-677 Safety in General?

Understanding MK-677's standalone safety profile helps contextualize what caffeine adds to the risk picture.

Key Trial Data

The landmark Phase III trial by Murphy et al. Published in the Journal of Clinical Endocrinology and Metabolism (N=292, 2-year duration) found that 25 mg/day MK-677 increased IGF-1 by 84% from baseline and increased lean body mass by 1.6 kg compared to placebo [7]. Common adverse effects included increased appetite (reported in 67% of participants), transient lower-extremity edema (19%), and mild fasting hyperglycemia (approximately 18% of the active arm showed fasting glucose increases above the normal reference range).

Serious adverse events included congestive heart failure exacerbations in older adults with pre-existing cardiac disease, which led to a protocol amendment limiting enrollment. This cardiac sensitivity makes the additive pressor risk from high-dose caffeine particularly relevant for older users.

Regulatory Status

MK-677 is not approved by the FDA for any therapeutic indication. It has been investigated in Phase II and III trials for GH deficiency, muscle wasting, and osteoporosis, but no sponsor has pursued or received approval [8]. Products sold online as MK-677 are research chemicals subject to no manufacturing oversight, and a 2023 independent laboratory analysis found that approximately 40% of tested samples contained less than 90% of the labeled dose, with some containing unidentified compounds [9].

Are There People Who Should Avoid This Combination Entirely?

Yes. Certain groups face disproportionate risk from combining MK-677 and significant caffeine intake.

Absolute Avoidance Scenarios

People with type 2 diabetes or an HbA1c above 6.5% should not add MK-677 without direct endocrinologist supervision, and high-dose caffeine compounds that risk further. MK-677 is formally contraindicated (by investigational protocol standards, not FDA labeling, since no FDA label exists) in active malignancy, because GH and IGF-1 elevation may promote tumor growth [10].

High-Caution Groups

Individuals with stage 2 hypertension (systolic above 140 mmHg), a history of arrhythmia, or sleep apnea face amplified risk. Caffeine worsens sleep-disordered breathing acutely through arousal mechanisms, and MK-677 independently worsens sleep apnea severity. The 1998 Annals trial reported that sleep apnea incidence was higher in the MK-677 arm compared to placebo [2].

Women who are pregnant or breastfeeding should avoid MK-677 entirely; caffeine safety thresholds in pregnancy (below 200 mg/day per ACOG guidelines) are already conservative, and adding a GH secretagogue with no pregnancy safety data is not defensible [11].

What Should You Monitor If You Are Already Taking Both?

If someone is already using MK-677 and caffeine together, stopping abruptly is not necessary, but a structured monitoring plan is.

Blood Pressure Monitoring

Check blood pressure at home using a validated cuff at the same time each morning, before caffeine intake. Log readings for at least 2 weeks. A sustained average above 135/85 mmHg at home warrants clinical consultation. The American Heart Association defines home hypertension as readings consistently above 130/80 mmHg [6].

Glucose Monitoring

A fasting fingerstick glucose test or laboratory fasting glucose test once monthly is adequate for most people. HbA1c every 3 months gives a more complete picture of glycemic trend over time. If fasting glucose exceeds 125 mg/dL on two separate occasions, that meets the diagnostic threshold for diabetes per the American Diabetes Association's 2024 Standards of Care [12].

Signs That Warrant Stopping Immediately

Chest pain, palpitations lasting more than a few minutes, severe headache, or visual changes while using this combination require urgent medical evaluation. These are possible signs of hypertensive urgency or cardiac arrhythmia and are not manageable with dose adjustment alone.

Practical Recommendations

• Keep caffeine at or below 200 mg/day while using MK-677.
• Take MK-677 at bedtime; confine caffeine to before noon.
• Establish baseline blood pressure and fasting glucose before starting.
• Recheck both at 4 weeks and again at 12 weeks.
• Avoid this combination if you have type 2 diabetes, stage 2 hypertension, a history of cardiac arrhythmia, or active cancer.
• Purchase MK-677 only from suppliers who provide third-party certificate of analysis, given the high rate of mislabeled products in the research-chemical market.

Fasting glucose at or below 99 mg/dL and home systolic blood pressure at or below 130 mmHg on two consecutive 2-week monitoring periods are the two specific targets that indicate the combination is being tolerated within an acceptable range.